{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Long J"],"funding":["National Natural Science Foundation of China"],"pagination":["e2202590"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11468017"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["12(13)"],"pubmed_abstract":["mRNA-based therapy has emerged as the most promising nucleic acid therapy in the fight against COVID-19. However, a safe and efficacious systemic delivery remains a challenge for mRNA therapy. Lipid nanoparticles (LNPs) are currently widely used in mRNA delivery vehicles. Here, a series of ionizable LNPs is rationally designed. YK009-LNP is an optimal delivery platform to carry mRNA. YK009-LNP exhibits higher mRNA delivery efficiency, a more favorable biodistribution pattern, and better safety than the approved MC3-LNP. In addition, mRNA encoding severe acute respiratory syndrome coronavirus 2 Omicron receptor binding domain protein is synthesized and intramuscular administration of mice with YK009-LNP-Omicron mRNA induces a robust immune response and immune protective effect. A novel mRNA delivery vehicle with more powerful delivery efficiency and better safety than the approved LNPs is provided here."],"journal":["Advanced healthcare materials"],"pubmed_title":["Novel Ionizable Lipid Nanoparticles for SARS-CoV-2 Omicron mRNA Delivery."],"pmcid":["PMC11468017"],"funding_grant_id":["81830101"],"pubmed_authors":["Yang J","Yu C","Lu H","Zhang Z","Long J","Wang S","Zhang H","Cao Y","Wang X","Wang H","Sang Y","Song G"],"additional_accession":[]},"is_claimable":false,"name":"Novel Ionizable Lipid Nanoparticles for SARS-CoV-2 Omicron mRNA Delivery.","description":"mRNA-based therapy has emerged as the most promising nucleic acid therapy in the fight against COVID-19. However, a safe and efficacious systemic delivery remains a challenge for mRNA therapy. Lipid nanoparticles (LNPs) are currently widely used in mRNA delivery vehicles. Here, a series of ionizable LNPs is rationally designed. YK009-LNP is an optimal delivery platform to carry mRNA. YK009-LNP exhibits higher mRNA delivery efficiency, a more favorable biodistribution pattern, and better safety than the approved MC3-LNP. In addition, mRNA encoding severe acute respiratory syndrome coronavirus 2 Omicron receptor binding domain protein is synthesized and intramuscular administration of mice with YK009-LNP-Omicron mRNA induces a robust immune response and immune protective effect. A novel mRNA delivery vehicle with more powerful delivery efficiency and better safety than the approved LNPs is provided here.","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 May","modification":"2026-06-13T05:40:59.255Z","creation":"2025-04-06T12:31:28.879Z"},"accession":"S-EPMC11468017","cross_references":{"pubmed":["36716702"],"doi":["10.1002/adhm.202202590"]}}